Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)
This page covers all Chemotherapy combination (topoisomerase I inhibitor + antimetabolite) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Topoisomerase I; thymidylate synthase, VEGFR, FGFR, KIT, RET, RAF (regorafenib); Topoisomerase I (DIBIRI/irinotecan), Topoisomerase I, Tubulin.
Targets
Topoisomerase I; thymidylate synthase · VEGFR, FGFR, KIT, RET, RAF (regorafenib); Topoisomerase I (DIBIRI/irinotecan) · Topoisomerase I, Tubulin · Topoisomerase I · Topoisomerase I; Thymidylate synthase · Thymidylate synthase (5-FU); Topoisomerase I (Irinotecan) · Thymidylate synthase (5-FU), Topoisomerase I (irinotecan) · Topoisomerase I, thymidylate synthase · Topoisomerase I; DNA (cisplatin cross-linking) · Topoisomerase I and thymidylate synthase
Marketed (1)
- Irinotecan, 5FU, leucovorin · Asan Medical Center · Oncology
This combination chemotherapy regimen inhibits DNA synthesis and cell division through topoisomerase I inhibition and fluoropyrimidine-mediated nucleotide antagonism.
Phase 3 pipeline (23)
- Regorafenib and DIBIRI · Sun Yat-sen University · Oncology
Regorafenib is a multi-kinase inhibitor that blocks tumor angiogenesis and growth signaling, while DIBIRI (dinitro-irinotecan) is a lipophilic prodrug of irinotecan that enhances drug delivery to tumors. - Topotecan, dexamethasone, vincristine · St. Jude Children's Research Hospital · Oncology
Topotecan is a topoisomerase I inhibitor, vincristine is a vinca alkaloid that disrupts microtubule formation, and dexamethasone is a corticosteroid that suppresses inflammation and immune response. - Irinotecan Injection · Chinese Academy of Medical Sciences · Oncology
Irinotecan is a topoisomerase I inhibitor that prevents DNA religation during replication, leading to DNA damage and cancer cell death. - Irinotecan/Tegafur · Sunshine Lake Pharma Co., Ltd. · Oncology
Irinotecan inhibits topoisomerase I to prevent DNA unwinding during replication, while tegafur is a prodrug of fluorouracil that inhibits thymidylate synthase to disrupt nucleotide synthesis. - Irinotecan liposome、5-Fluorouracil、Leucovorin · Jiangsu HengRui Medicine Co., Ltd. · Oncology
This combination regimen uses liposomal irinotecan (a topoisomerase I inhibitor) plus 5-fluorouracil and leucovorin to inhibit DNA replication and repair in cancer cells. - Oral Topotecan · Accelerated Community Oncology Research Network · Oncology
Oral topotecan inhibits topoisomerase I, an enzyme required for DNA replication, causing DNA damage and cancer cell death. - Infusional 5-FU/LV with Irinotecan · Pfizer · Oncology
This combination chemotherapy regimen inhibits DNA synthesis and topoisomerase I to kill rapidly dividing cancer cells. - "FOLFIRI" cures · Centre Hospitalier Universitaire Dijon · Oncology
FOLFIRI is a chemotherapy regimen that combines three drugs to inhibit DNA synthesis and cell division, primarily used to treat colorectal cancer. - Irinotecan plus 5-FU plus leucovorin · ERYtech Pharma · Oncology
This combination of irinotecan (a topoisomerase I inhibitor), 5-fluorouracil (a nucleotide analog), and leucovorin (a folate cofactor) works together to inhibit DNA synthesis and repair in cancer cells. - Hydroxycamptothecin for Injection · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Oncology
Hydroxycamptothecin inhibits topoisomerase I, preventing DNA relaxation and causing DNA damage in rapidly dividing cancer cells. - Intravenous topotecan/cisplatin · GlaxoSmithKline · Oncology
This combination uses topotecan to inhibit topoisomerase I and cisplatin to cross-link DNA, together inducing cancer cell death through multiple mechanisms. - capecitabine-irinotecan · Dutch Colorectal Cancer Group · Oncology
Capecitabine-irinotecan combines a prodrug of fluorouracil with a topoisomerase I inhibitor to target rapidly dividing cancer cells. - FOLFIRI regimen · National Cancer Institute (NCI) · Oncology
FOLFIRI is a chemotherapy regimen that combines three drugs to inhibit DNA synthesis and cell division, primarily targeting rapidly dividing cancer cells. - Irinotecan Liposomal · The First Affiliated Hospital of Zhengzhou University · Oncology
Irinotecan liposomal is a topoisomerase I inhibitor encapsulated in liposomes that prevents DNA religation during replication, leading to cell death. - Liposomal irinotecan · St. Jude Children's Research Hospital · Oncology
Liposomal irinotecan is a nanoparticle formulation of the topoisomerase I inhibitor irinotecan that delivers the chemotherapy agent to tumor cells while reducing systemic toxicity. - CPT-11 (Irinotecan) · Epidemiological and Clinical Research Information Network · Oncology
CPT-11 (irinotecan) is a topoisomerase I inhibitor that prevents DNA unwinding and repair, leading to DNA damage and cancer cell death. - MM-398 · Ipsen · Oncology
MM-398 is a liposomal formulation of irinotecan that delivers the topoisomerase I inhibitor directly to tumor cells while reducing systemic toxicity. - Oral Capecitabine with Irinotecan · Pfizer · Oncology
Capecitabine is converted to 5-fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while irinotecan inhibits topoisomerase I to prevent DNA unwinding during replication, together producing synergistic cytotoxic effects against cancer cells. - Vincristine and Topotecan · St. Jude Children's Research Hospital · Oncology
Vincristine is a vinca alkaloid that inhibits microtubule formation, while Topotecan is a topoisomerase I inhibitor that prevents DNA replication. - Irinotecan Liposomal Injection [Onivyde] · Seoul National University Hospital · Oncology
Irinotecan liposomal injection is a topoisomerase I inhibitor encapsulated in liposomes that prevents DNA unwinding and causes cancer cell death. - Irinotecan + 5 FU + folinic acid · Pfizer · Oncology
This combination chemotherapy regimen kills cancer cells by inhibiting topoisomerase I (irinotecan) and blocking thymidylate synthase (5-FU with folinic acid potentiation). - HYCAMTIN, oral capsules · GlaxoSmithKline · Oncology
Topotecan inhibits topoisomerase I, an enzyme required for DNA replication, causing DNA damage and cell death in rapidly dividing cancer cells. - Irinotecan Based Chemotherapy · Amgen · Oncology
Irinotecan is a topoisomerase I inhibitor that prevents DNA religation during replication, leading to DNA damage and cancer cell death.
Phase 2 pipeline (4)
- CMAB009 plus Irinotecan · Shanghai Zhangjiang Biotechnology Limited Company · Oncology
CMAB009 is a PD-1 inhibitor, and Irinotecan is a topoisomerase I inhibitor. - Cyclophosphamide and Topotecan · Children's Medical Center Dallas · Oncology
This combination uses cyclophosphamide as an alkylating agent to damage cancer cell DNA and topotecan as a topoisomerase I inhibitor to prevent DNA repair, working synergistically to kill cancer cells. - CPT-11 based regimens · Daiichi Sankyo Co., Ltd. · Oncology
CPT-11 is a topoisomerase I inhibitor that works by stabilizing the cleavage complex of DNA and RNA, thereby inhibiting DNA replication and transcription. - G17DT-Irinotecan · Cancer Advances Inc. · Oncology
G17DT-Irinotecan is a topoisomerase I inhibitor, which works by blocking the enzyme topoisomerase I and preventing DNA replication in cancer cells.
Patent intelligence
- topoisomerase i inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates